Escient Pharmaceuticals, Inc clinical trials

Acquired by Incyte Corporation, May 30, 2024 · source ↗

The registry lists 6 studies whose lead sponsor is Escient Pharmaceuticals, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 19, 2025.

Before and after it joined Incyte Corporation

First submitted before Escient Pharmaceuticals, Inc became part of Incyte Corporation: 5
First submitted after Escient Pharmaceuticals, Inc became part of Incyte Corporation: 1
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 5
Terminated: 1

Phase

Phase 1: 3
Phase 2: 3

Where

United States: 5
Canada: 4
Netherlands: 3
Spain: 3
Germany: 2
Australia: 1

Registry sponsor names on this page

Escient Pharmaceuticals, Inc6 studies

Something wrong with this grouping? Tell us on the Incyte Corporation page.

Studies

Recruiting first, then most recently updated. Showing 6 of 6. All Incyte Corporation studies →

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous UrticariaTerminatedNCT06077773Phase 2
Sponsor listed in the registry: Escient Pharmaceuticals, Inc · First submitted before Escient Pharmaceuticals, Inc became part of Incyte Corporation
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic DermatitisCompletedNCT06144424Phase 2
Sponsor listed in the registry: Escient Pharmaceuticals, Inc · First submitted before Escient Pharmaceuticals, Inc became part of Incyte Corporation
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic PruritusCompletedNCT04510090Phase 1
Sponsor listed in the registry: Escient Pharmaceuticals, Inc · First submitted before Escient Pharmaceuticals, Inc became part of Incyte Corporation
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing CholangitisCompletedNCT05525520Phase 2
Sponsor listed in the registry: Escient Pharmaceuticals, Inc · First submitted before Escient Pharmaceuticals, Inc became part of Incyte Corporation
An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral AdministrationCompletedNCT06645704Phase 1
Sponsor listed in the registry: Escient Pharmaceuticals, Inc · First submitted after Escient Pharmaceuticals, Inc became part of Incyte Corporation
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible UrticariaCompletedNCT06050928Phase 1
Sponsor listed in the registry: Escient Pharmaceuticals, Inc · First submitted before Escient Pharmaceuticals, Inc became part of Incyte Corporation